Pall and CMC Biologics pave the way with multicolumn-chromatography-based downstream manufacturing
To cope with the increasing demand on downstream processing (DSP), chromatography columns generally must be cycled multiple times, creating additional holding time when the load material is not being processed. As such, the biopharmaceutical industry would benefit greatly from an improved process to more efficiently use the sorbents (i.e. capture step or polishing unit operations).
Multi-column chromatography (MCC) technology offers prominent productivity gains and economic advantages for DSP. Despite the upfront capital expenses required for adopting MCC technology, the significant cost savings achieved from sorbent reduction and productivity improvement make it a justifiable investment, which benefits drug developers of any kind in the long run. CMC Biologics is one of first CDMOs to offer multi-column chromatography using Cadence™ BioSMB systems to their customers.
Immediate results have included reduced clinical manufacturing costs through improved sorbent utilization.